---
title: "Seanergy Maritime Holdings Corp. Stock 12‑Month Price Target Raised to $21.3, Implies 43% Upside"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287961865.md"
description: "Seanergy Maritime Holdings Corp.'s stock price target has been raised from $20.3 to $21.3, indicating a potential upside of 43%. The consensus rating remains a 'Buy' from 5 analysts, with forecasts ranging from $18 to $25.5 per share."
datetime: "2026-05-28T19:20:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287961865.md)
  - [en](https://longbridge.com/en/news/287961865.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287961865.md)
generator: "portal-rs"
---

# Seanergy Maritime Holdings Corp. Stock 12‑Month Price Target Raised to $21.3, Implies 43% Upside

-   According to estimates from 5 analysts, Seanergy Maritime Holdings Corp. stock's average price target has risen from $20.3 to $21.3, with forecasts ranging from $18 to $25.5 per share
-   Based on the May 27 closing price, the updated target implies approximately 43% potential upside
-   Consensus rating remains at “Buy” across 5 covering analysts, with 5 Buys, 0 Holds and 0 Sells

Explore more price target data and ratings for Seanergy Maritime Holdings Corp. on the , and track all previous and future analyst recommendations for Seanergy Maritime Holdings Corp. in the dedicated News Flow.

**Disclaimer**

Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [SHIP.US](https://longbridge.com/en/quote/SHIP.US.md)

## Related News & Research

- [Seanergy Maritime director Christina Anagnostara disposes of 15,000 common shares worth $257,850](https://longbridge.com/en/news/295273910.md)
- [Seanergy Maritime CFO Stavros Gyftakis sells 3,300 shares for $48,873](https://longbridge.com/en/news/292810908.md)
- [Does Toro (TTC) Prioritizing Productivity Gains Hint At A Deeper Shift In Its Profit Playbook?](https://longbridge.com/en/news/298119884.md)
- [Nektar Therapeutics (NKTR) Lands Lancet Backing, Is The Upside Already Priced In?](https://longbridge.com/en/news/298137481.md)
- [Client Rollouts At Alkami Stock Have Changed Its Investment Story](https://longbridge.com/en/news/298321107.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**